Board of Directors

Pankaj Mohan, Ph.D.

Founder and CEO

Dr. Mohan founded Oncobiologics in 2011 after a distinguished 20+ year career in the global biopharmaceutical industry.  Most recently, Dr. Mohan headed  Business Operations and Portfolio Management for a division of Bristol-Myers Squibb, where he was instrumental in expanding the business’ biologics pipeline.  He also held prior positions at Genentech and Eli Lilly and Company, where he led various bioprocess engineering functions.   Dr. Mohan also served as Assistant Professor (Lecturer/Fellow), at the Advanced Centre for Biochemical Engineering  at University College London.

During his career, Dr. Mohan played an important role in the development and manufacture of multiple blockbuster biopharmaceutical drugs. He planned, initiated and led a state of the art biologics R&D organization, and most recently led the acquisition of small biotech companies and multiple biologics molecule assets.

He earned his Ph.D. in Biochemical  Engineering at the School of Chemical Engineering, University of Birmingham, Birmingham, United Kingdom;  his MBA specializing in Finance Management from Middlesex University Business School, London, United Kingdom, and his Bachelor of Chemical Engineering at the Indian Institute of Technology in India.

Dr. Mohan has authored a book on Pharmaceutical Manufacturing published by McGraw Hill and is the author of more than 30 publications.

 

Scott Canute


Mr. Canute is a former President at both Eli Lilly and Genzyme. Over the course of his 30-year career, Mr. Canute played a vital role in leading Eli Lilly’s global manufacturing operations. Most recently, he spent more than a year as President of Global Manufacturing and Corporate Operations for Genzyme, where he led a major turnaround effort. Scott earned a Master of Business Administration from the Harvard Business School. He also earned a B.S. in Chemical Engineering at the University of Michigan, where he graduated with Highest Honors.

 

 

 

Donald J. Griffith, C.P.A. — Chief Financial Officer

Don Griffith brings to Oncobiologics more than 30 years of experience in finance and accounting, including a partner position in the New Jersey accounting firm of Stolz & Griffith. Previously, his  roles included CFO and financial leadership positions  and more than 10 years in corporate finance with Exxon corporation. Don is a member of New Jersey Society of CPAs and the American Institute of CPAs.

 

Rama Rao, Ph.D.

Dr. Rao recenty retired as President of Vimta Labs, Ltd., a leading India-based Contract Research Organization engaged in providing services to drug discovery and drug development.  He was also a past Managing Director of Indian Medicines Pharmaceutical Corporation Ltd., a Government of India Enterprise focused on manufacture of medicines for government institutions.    Dr. Rao led India Medicines through a scientific, technical and financial turnaround, re-establishing its viability for the Government of India.  He was also head of Research and Development, Quality Control and Management Services for Hindustan Organic Chemicals, Ltd. Dr. Rao also held several scientific and R&D positions, and is widely published.  He earned his Ph.D. in Chemistry and his M.Sc. in Organic Chemistry from the University of Roorkee.

 


 

Board Observers:

 

Todd C. Brady, M.D., Ph.D.

Dr. Brady is Chief Executive Officer, President & Director of Aldeyra Therapeutics.  He has more than 18 years of pharmaceutical clinical and business development experience.  Dr. Brady was an entrepreneur-in-residence and principal at Domain Associates, where he led institutional financing in numerous biotechnology companies from 2004 to 2013.  Dr. Brady holds an M.D. from Duke University Medical School, a Ph.D. from Duke University Graduate School, and an A.B. from Dartmouth College.
 
 

Balu N. Balasubramanian, Ph.D.

Dr. Balasubramanian currently leads the Pharma Innovation Sourcing Center.  He is a former executive from Bristol-Myers Squibb (most recently Managing Director of the BMS-Biocon R&D Center) with over 25 years of scientific and management experience in drug discovery and early clinical development.

 

Robert A. Cole

Bob Cole recently retired after a distinguished 30+ year career at Eli Lilly & Company and Genzyme.  His leadership roles included engineering and product development.  He retired in 2007 as Vice President, Global Parenteral Operations, Global Engineering, Safety and Environmental Affairs.

 

W. Raymond Felton

Ray is Co-Managing partner at the law firm of Greenbaum Rowe & Smith in Iselin, New Jersey. He is an expert in corporate and securities law, including a focus on private companies.  Ray has been listed in The Best Lawyers in America since 1994.  He is also the author of several treatises on corporate transactions and compensation issues.